Hisatsugu Ohori

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer

Jun Watanabe, Kei Muro, Kohei Shitara et al. · JAMA · 2023 · 258 citations · Full text

Medicine, Oncology, Pharmacology +17

Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer

Hisatsugu Ohori, Hiroyuki Yamakoshi, Masaki Tomizawa et al. · Molecular Cancer Therapeutics · 2006 · 243 citations · Full text

Medicine, Oncology, Pharmacology +14

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

Kohei Shitara, Kei Muro, Jun Watanabe et al. · Nature Medicine · 2024 · 110 citations · Full text

Medicine, Oncology, Pharmacology +17

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

Yasuhide Yamada, Tadamichi Denda, Makio Gamoh et al. · Annals of Oncology · 2017 · 91 citations · Full text

Medicine, Oncology, Pharmacology +10

Structure–activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof

Hiroyuki Yamakoshi, Hisatsugu Ohori, Chieko Kudo et al. · Bioorganic & Medicinal Chemistry · 2009 · 71 citations

Pharmacy, Medicinal Chemistry, Pharmacology +8